Compare ARK Genomic Revolution ETF (ARKG) vs Novavax Inc (NVAX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Novavax Inc — how do they compare? ARK Genomic Revolution ETF trades at $40.83, while Novavax Inc trades at $9.27 (market cap $1.53B). The key difference: ARK Genomic Revolution ETF is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.
| ARKG | NVAX | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $43.57 | $11.19 |
52-Week Low | $23.09 | $6.22 |
Market Cap | — | $1.53B |
Enterprise Value | — | $1.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Novavax (NVAX) trades at $9.33, down 0.74% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $14.00. The company reported revenue of $1.12 billion in 2025, swinging to a net income of $440.30 million, but faces negative cash flow and a negative shareholder equity position. Recent news highlights shareholder dissent at the AGM and investor attention amid vaccine stock volatility.
The outlook is mixed: strong valuation ratios and recent earnings beats suggest upside potential, but persistent cash burn and competitive pressures in the vaccine market pose significant risks. Analyst sentiment is predominantly bullish, yet the stock's performance remains sensitive to clinical developments and market sentiment toward biotech stocks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
